Suppr超能文献

新型Src激酶抑制剂[7-(2,6-二氯苯基)-5-甲基-苯并[1,2,4]三嗪-3-基]-[4-(2-吡咯烷-1-基乙氧基)-苯基]-胺(TG100435)及其N-氧化物代谢物通过含黄素单加氧酶和细胞色素P450还原酶的循环转化

Cyclic conversion of the novel Src kinase inhibitor [7-(2,6-dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine (TG100435) and Its N-oxide metabolite by flavin-containing monoxygenases and cytochrome P450 reductase.

作者信息

Kousba Ahmed, Soll Richard, Yee Shiyin, Martin Michael

机构信息

Department of Pharmaceutical Property Assessment, TargeGen Inc, San Diego, CA 92121, USA.

出版信息

Drug Metab Dispos. 2007 Dec;35(12):2242-51. doi: 10.1124/dmd.107.017384. Epub 2007 Sep 19.

Abstract

[7-(2,6-Dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine (TG100435) is a novel multi-targeted Src family kinase inhibitor with demonstrated anticancer activity in preclinical species. Potent kinase inhibition is associated with TG100435 and its major N-oxide metabolite [7-(2,6-dichlorophenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-{4-[2-(1-oxy-pyrrolidin-1-yl)-ethoxy]-phenyl}-amine (TG100855). The objectives of the current study were to identify the hepatic enzyme(s) responsible for 1) the total metabolic flux of TG100435, 2) the formation of TG100855, and 3) the subsequent metabolism of TG100855. Flavin-containing monooxygenases (FMO) and cytochrome P450 monooxygenases (P450s) contribute to TG100435 total metabolic flux. TG100435 metabolic flux was completely inhibited by methimazole and ketoconazole, suggesting only FMO- and CYP3A4-mediated metabolism. TG100855 formation was markedly inhibited (~90%) by methimazole or heat inactivation (>99%). FMO3 was the primary enzyme responsible for TG100855 formation. In addition, an enzyme mediated retroreduction of TG100855 back to TG100435 was observed. The N-oxidation reaction was approximately 15 times faster than the retroreduction reaction. Interestingly, the retroreduction of TG100855 to TG100435 in recombinant P450 or liver microsomes lacked inhibition by the P450 inhibitors. TG100435 formation in the human liver microsomes or recombinant P450 increased as a function of cytochrome P450 reductase activity, suggesting potential involvement of cytochrome P450 reductase. The results of this in vitro study demonstrate the potential of TG100435 and TG100855 to be interconverted metabolically. FMO seem to be the major N-oxidizing enzymes, whereas cytochrome P450 reductase seems to be responsible for the retroreduction reaction.

摘要

[7-(2,6-二氯苯基)-5-甲基-苯并[1,2,4]三嗪-3-基]-[4-(2-吡咯烷-1-基乙氧基)-苯基]-胺(TG100435)是一种新型多靶点Src家族激酶抑制剂,在临床前动物模型中已显示出抗癌活性。强效激酶抑制作用与TG100435及其主要的N-氧化物代谢产物[7-(2,6-二氯苯基)-5-甲基-苯并[1,2,4]三嗪-3-基]-{4-[2-(1-氧代-吡咯烷-1-基)-乙氧基]-苯基}-胺(TG100855)相关。本研究的目的是确定负责以下方面的肝酶:1)TG100435的总代谢通量;2)TG100855的形成;3)TG100855随后的代谢。含黄素单加氧酶(FMO)和细胞色素P450单加氧酶(P450s)参与了TG100435的总代谢通量。甲巯咪唑和酮康唑可完全抑制TG100435的代谢通量,提示仅存在FMO和CYP3A4介导的代谢。甲巯咪唑或热灭活(>99%)可显著抑制(约90%)TG100855的形成。FMO3是负责TG100855形成的主要酶。此外,还观察到一种酶介导TG100855逆向还原回TG100435。N-氧化反应比逆向还原反应快约15倍。有趣的是,在重组P450或肝微粒体中,TG100855逆向还原为TG100435不受P450抑制剂的抑制。在人肝微粒体或重组P450中,TG100435的形成随细胞色素P450还原酶活性而增加,提示细胞色素P450还原酶可能参与其中。这项体外研究结果表明TG100435和TG100855在代谢上具有相互转化的潜力。FMO似乎是主要的N-氧化酶,而细胞色素P450还原酶似乎负责逆向还原反应。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验